Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted immunoproteomics of cerebrospinal fluid in disease-modifying treatment-naïve Multiple Sclerosis patients

ABSTRACT: Targeted immunoproteomics of cerebrospinal fluid in disease-modifying treatment-naïve Multiple Sclerosis patients

PROVIDER: PRJNA1079393 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Transcriptional profiling of cerebrospinal fluid cells of multiple sclerosis patients

Project description:RNA was isolated from fresh cerebrospinal fluid samples of multiple sclerosis and control patients and analyzed by hybridization of HG U133 plus 2.0 arrays in order to investigate disease mechanisms of multiple sclerosis and to identify transcriptional biomarker

2014-06-01 | E-MTAB-2374 | biostudies-arrayexpress

Human cerebrospinal fluid autoantibody lipid microarray profiling

Project description:This SuperSeries is composed of the following subset Series: GSE37664: Human cerebrospinal fluid autoantibody lipid microarray profiling (Fig. 1A) GSE37670: Human cerebrospinal fluid autoantibody lipid microarray profiling (Fig. 2A) GSE37826: Human cerebrospinal fluid autoantibody lipid microarray profiling (Fig. 2C) Refer to individual Series

2012-05-08 | E-GEOD-37830 | biostudies-arrayexpress

Cerebrospinal fluid

Project description:Cerebrospinal fluid Genome sequencing

| PRJNA856347 | ENA

Targeted immunoproteomics of cerebrospinal fluid in disease-modifying treatment-naïve Multiple Sclerosis patients

Project description:We performed a retrospective study on CSF from 20 DMT-naïve MS patients to investigate the correlation between intrathecal immune proteins and clinical MS phenotype.

2024-09-25 | GSE256426 | GEO

Transcription profiling by array of paired cerebrospinal fluid and peripheral blood lymphocyte samples from multiple sclerosis patients and controls with other non-inflammatory neurological disorders

Project description:We performed gene expression profiling on paired cerebrospinal fluid (CSF) and peripheral blood lymphocyte (PBL) samples from 26 Multiple sclerosis patients without immunomodulatory treatment sampled in relapse or in remission, and 18 controls with other non-inflammatory neurological disorders using Human Genome U133 plus 2.0 arrays (Affymetrix).

2009-12-02 | E-MTAB-69 | biostudies-arrayexpress

Human cerebrospinal fluid autoantibody lipid microarray profiling (Fig. 1A)

Project description:Lipids comprise 70% of the myelin sheath, and autoantibodies against lipids may contribute to the demyelination that characterizes multiple sclerosis (MS). We used lipid antigen microarrays and lipid mass spectrometry to identify bona fide lipid targets of the autoimmune response in MS brain and an animal model of MS to explore the role of the identified lipids in autoimmune demyelination. We found that autoantibodies in MS target a phosphate group in phosphatidylserine and oxidized phosphatidylcholine derivatives. Administration of these lipids ameliorated experimental autoimmune encephalomyelitis by suppressing activation and inducing apoptosis of autoreactive T cells, effects mediated by the lipids' saturated fatty-acid side chains. Thus, phospholipids represent a natural anti-inflammatory class of compounds that have potential as novel therapeutics for MS. Fig. 1A. Lipid-array profiling of IgG+IgM antibody reactivity in cerebrospinal fluid (CSF) samples from MS patients (relapsing remitting MS; secondary progressive MS; primary progressive MS), healthy controls, and other neurological disease controls. Lipid hits with the lowest FDR (q=0.048) were clustered according to their reactivity profiles. 48 different lipids were custom-spotted in duplicate using the CAMAG Automatic TLC Sampler (ATS4) robot to spray 200 nl of 10 to 100 pmol of lipids onto PVDF membranes affixed to the surface of microscope slides. The slides were probed with cerebrospinal fluid (CSF) from 59 human patient samples. 60 slides total: 18 relapsing-remitting MS, 14 secondary-progressive MS, 1 primary-progressive MS, 21 other neurological disease, 5 healthy control, 1 secondary Ab alone (not included in this submission). CSF diluted 1/10. HRP-conjugated secondary Ab (goat anti-human IgM/IgG) diluted 1/8000. ECL for 3 minutes.

2012-05-08 | E-GEOD-37664 | biostudies-arrayexpress

Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis

Project description:Cerebrospinal fluid (CSF) protects the central nervous system (CNS) and analyzing CSF aids the diagnosis of CNS diseases, but our understanding of CSF leukocytes remains superficial. Here, using single cell transcriptomics, we identified a specific border-associated composition and transcriptome of CSF leukocytes. Multiple sclerosis (MS) – an autoimmune disease of the CNS – increased transcriptional diversity in blood, but increased cell type diversity in CSF including a higher abundance of cytotoxic phenotype T helper cells. A new analytical approach, named cell set enrichment analysis (CSEA) identified a cluster-independent increase of follicular T helper (TFH) cells potentially driving the known expansion of B lineage cells in the CSF in MS. In mice, TFH cells accordingly promoted B cell infiltration into the CNS and the severity of MS animal models. Immune mechanisms in MS are thus highly compartmentalized and indicate ongoing local T/B cell interaction.

2019-12-10 | GSE138266 | GEO

miRNA expression in cerebrospinal fluid with moyamoya disease

Project description:We performed microarray analysis to determine the expression profiles of miRNAs in cerebrospinal fluid with moyamoya disease

2020-04-03 | GSE129792 | GEO

Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis

Project description:Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis

| PRJNA575241 | ENA

A cerebrospinal fluid microRNA analysis of progressive supranuclear palsy.

Project description:The cerebrospinal fluid miRNAs expression was markedly altered in the patients with progressive supranuclear palsy and controls.

2021-12-05 | GSE186921 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data